Document is current
Any future updates will be listed below
-
Authors
Super, Michael
Doherty, Edward J.
Cartwright, Mark J.
Seiler, Benjamin T.
Langellotto, Fernanda
Dimitrakakis, Nikolaos
White, Des A.
Stafford, Alexander G.
Karkada, Mohan
Graveline, Amanda R.
Horgan, Caitlin L.
Lightbown, Kayla R.
Urena, Frank R. https://orcid.org/0000-0002-0589-2963
Yeager, Chyenne D.
Rifai, Sami A.
Dellacherie, Maxence O.
Li, Aileen W.
Leese-Thompson, Collin
Ijaz, Hamza
Jiang, Amanda R.
Chandrasekhar, Vasanth
Scott, Justin M. https://orcid.org/0000-0003-4547-9994
Lightbown, Shanda L.
Ingber, Donald E. https://orcid.org/0000-0002-4319-6520
Mooney, David J. https://orcid.org/0000-0001-6299-1194
-
Funding
Funding for this research was provided by:
United States Department of Defense | Defense Advanced Research Projects Agency (W911NF-16-C-0050, W911NF-16-C-0050)
- License Information
-
More Information
Article History
Received: 12 May 2020
Accepted: 31 May 2021
First Online: 8 July 2021
Competing interests
: D.J.M. received sponsored research funding from Novartis, and has equity in Lyell and Attivare Therapeutics. D.E.I. is a founder, member of the board of directors and scientific advisory board, and equity holder in Boa Biomedical, Inc. M.S. is a founder and equity holder in BOA Biomedical. E.J.D., F.L. and B.T.S. are founders and have equity in Attivare Therapeutics. Inventors, patent applications: D.J.M., D.E.I., M.S., M.J.C., E.J.D., B.T.S., F.L., A.G.S., A.R.G., J.M.S. and D.A.W. For each patent, the serial number, country and patent number are provided: (1) 15/434,781; US; 10,813,988; (2) 17/015,177; US; (3) 2018-543154; Japan; 6854530; (4) 17753811; EPO; and (5) 202000000000; China. All other authors declare that they have no competing interests.
